A 21-year-old man with a T-5 spinal cord injury presents to the urgent care clinic where the nurse practitioner (NP) is working. He says he was out to dinner with a friend when he suddenly began to feel lightheaded. Now, he reports symptoms of diaphoresis, flushed face and neck, and severe headache. Upon assessment, the NP finds bradycardia and severe hypertension. Which of the following has NOT been used as treatment for autonomic dysreflexia?

Choice A reason: Minocycline is a tetracycline antibiotic and has not been established as a treatment for autonomic dysreflexia. While it has neuroprotective and anti-inflammatory properties in experimental models, it is not part of the clinical management protocol for autonomic dysreflexia. Choice B reason: OnabotulinumtoxinA (Botox) has been used in patients with neurogenic bladder or spasticity, which can contribute to autonomic dysreflexia. It helps reduce bladder overactivity and prevent triggering episodes. Choice C reason: Nifedipine, a calcium channel blocker, is commonly used to manage acute hypertension in autonomic dysreflexia. It reduces blood pressure quickly and is considered a first-line agent in emergent settings. Choice D reason: Lidocaine may be used to suppress afferent stimuli during procedures such as catheterization, which can trigger autonomic dysreflexia. It helps block nociceptive input and prevent reflex sympathetic discharge.